All News

keystone

RheumNow Podcast - 60/40/20 Interview with Dr. Ed Keystone

d Jack Cush, MD

Dr. Jack Cush interviews Professor Edward Keystone, MD (University of Toronto) on the origins and science behind the 60/40/20 benchmark and outcomes in rheumatoid arthritis.


Read Article
pso.arm_.JPG

Risankizumab for Active Psoriatic Arthritis

d Robert Chao, MD

The arsenal of therapeutics for psoriatic arthritis continues to increase. Risankizumab is an IL-23 inhibitor to the p19 subunit, currently being investigated for treatment of psoriatic arthritis.

Read Article
RA.Ow02.jpg

Better assessment and management of multimorbidity

d Mrinalini Dey, MD

Appropriate assessment and management of comorbidities and multimorbidity in patients with RA is vital for overall health and well-being of the patient, as well as to encourage treatment adherence, and address social, psychological and quality of life factors. 

Read Article
rachel.tate

Safety of Psoriatic Biologics in Pregnancy

d Jack Cush, MD

Little is known about the safety of newer biologic use during pregnancy, especially in patients who either conceive while on a biologic or must remain on a biologic during pregnancy (often the case with IBD and inflammatory arthritis).

Read Article
Pipeline

Emerging Therapies in Spondyloarthritis: A Promising Pipeline

d Olga Petryna, MD

Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.

Read Article
jon.kay

Does Control of Inflammation Lower Cancer Risk?

d Jack Cush, MD

Dr. Jonathan Kay's provocative video addresses whether the increased cancer risk associated with tofacitinib (Tofa) seen in the Pfizer Oral Surveillance (1133) study represents a real increased risk, an increased risk relative to a decreased risk with TNF inhibitors (TNFi) or an actual decreased cancer risk (unknown as there was no placebo comparator in this trial).

Read Article
Dr. Janet Pope and Dr. Jeffrey Sparks discuss the importance of lung and several lung-related abstracts presented at the ACR21 annual meeting. https://t.co/s5sl6tdKwP

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast - 60/40/20 Interview with Dr. Ed Keystone https://t.co/gLUfazvsXA

Links:

Dr. John Cush RheumNow ( View Tweet)

Multimorbidity, the presence of multiple overlapping chronic comorbid conditions, is increasingly common at first presentation of rheumatoid arthritis (RA), increasing as a person gets older and/or during disease progression. https://t.co/L6NJhVwOws https://t.co/GgRSCaYTZ6

Links:

Dr. John Cush RheumNow ( View Tweet)
"The reasonable man adapts himself to the world; the unreasonable one persists in trying to adapt the world to himself. Therefore, all progress depends on the unreasonable man." - George Bernard Shaw https://t.co/9bAJfkF7lH
Dr. John Cush RheumNow ( View Tweet)
Flare Patterns in Autoinflammatory Syndrome During Pandemic: Dr. Yuz Yusof ( @Yuz6Yusof) discusses abstract #1083 presented at the #ACR21 annual meeting. https://t.co/i0VU3NEe7F https://t.co/DZkB5TgG3N

Links:

Dr. John Cush RheumNow ( View Tweet)
RA Treatment Conundrums: Dr. Janet Pope ( @Janetbirdope ) reviews abstracts #1252, #1442, #1438, #1444 and #1443 at the #ACR21 annual meeting. https://t.co/ftlRAq0CNK https://t.co/nnT37wG8l9

Links:

Dr. John Cush RheumNow ( View Tweet)

Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares Drs.Cush, Yusof, Mehta, Petryna and Tate review autoinflammatory data presented at #ACR21. @Yuz6Yusof @bella_mehta @DrPetryna @uptoTate https://t.co/oeAprkSBWZ https://t.co/1g9yRRFJqf

Links:

Dr. John Cush RheumNow ( View Tweet)
SLE and Health-Related Quality of Life: Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract #1261 presented at the #ACR21 annual meeting. https://t.co/yLPBfId6tL https://t.co/09U4nUT9c7

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Session Review: Dr. Arthur Kavanaugh discussed the FDA session presented at the ACR21meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more. https://t.co/5YkbzDv0YR https://t.co/MS9KNIfm2m

Links:

Dr. John Cush RheumNow ( View Tweet)
The Last CBD Trial: Dr. David Liew ( @drdavidliew) discusses abstract #1456 presented at the #ACR21 annual meeting. https://t.co/Kw3h2vTJkv https://t.co/WZGV7iOFlA

Links:

Dr. John Cush RheumNow ( View Tweet)
Does Control of Inflammation Lower Cancer Risk? https://t.co/9dHwXmzktZ https://t.co/iPP09Bk3P3

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of PSA Studies on Monday: Dr. Rachel Tate ( @uptoTate) discusses abstracts #1444 and #0182 presented at the #ACR21 annual meeting. https://t.co/yWSQtr32su

Links:

Dr. John Cush RheumNow ( View Tweet)

COVID-19 in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica Dr. Bella Mehta ( @bella_mehta) interviews Dr. Sebastian Sattui about abstract #0952 presented at the #ACR21 annual meeting. https://t.co/BYyz0Xj1Fj

Links:

Dr. John Cush RheumNow ( View Tweet)

Uveitis and Prevalence of Psoriasis in axSpA: Dr. Robert Chao ( @doctorRBC) discusses the best SpA abstracts he saw at the #ACR21 annual meeting: abstracts #1324 and #1311. https://t.co/6zARkjsoCg

Links:

Dr. John Cush RheumNow ( View Tweet)

×